Propanc Biopharma, Inc.

PPCB

$1.00

-1.96%

2026-09-04 11:44:36 EDT-$0.02

Healthcare

Biotechnology

NASDAQ

Active Trading

Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on ...

Insider Transactions of PPCB

Acquisitions (A)

Since May 14, 2019

Disposals (D)

Since May 14, 2019

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jul 5, 2023	ZELINGER JOSEF	director	Common Stock Purchase Warrant	A	15,000,000	$0.01
Aug 17, 2021	Kenyon Julian Norman	director, officer: Chief Scientific Officer	Common stock, par value $0.001	A	3,420,000	—
Aug 17, 2021	Nathanielsz James Andrew	director, officer: CEO/CFO	Common stock, par value $0.001	A	5,928,000	—
Aug 17, 2021	Nathanielsz James Andrew	director, officer: CEO/CFO	Common stock, par value $0.001	A	2,800,000	—
Aug 17, 2021	ZELINGER JOSEF	director	Common stock, par value $0.001	D	0	—

Insider Trading Snapshot

Acquisitions (A)

Disposals (D)

Total Shares Bought

85,648,000

Total Shares Sold

Monthly Insider Activity

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Transactions by Title - Shares

X-axis: shares, sorted by total shares desc

Transactions by Title - Counts

X-axis: counts, sorted by A+D counts desc

Key People: Buy/Sell Activity and Price

Nathanielsz James Andrew

director, officer: CEO/CFO • 4 txns

Kenyon Julian Norman

director, officer: Chief Scientific Officer • 3 txns

ZELINGER JOSEF

director • 2 txns

Campiciano Carlo M

officer • 1 txns

Transactions Table

Date	Executive	Title	Security	Side	Shares	Price	Value
Jul 5, 2023	ZELINGER JOSEF	director	Common Stock Purchase Warrant	A	15,000,000	$0.01	$150,000.00
Aug 17, 2021	Kenyon Julian Norman	director, officer: Chief Scientific Officer	Common stock, par value $0.001	A	3,420,000	—	—
Aug 17, 2021	Nathanielsz James Andrew	director, officer: CEO/CFO	Common stock, par value $0.001	A	5,928,000	—	—
Aug 17, 2021	Nathanielsz James Andrew	director, officer: CEO/CFO	Common stock, par value $0.001	A	2,800,000	—	—
Aug 17, 2021	ZELINGER JOSEF	director	Common stock, par value $0.001	D	0	—	—
Jun 24, 2019	Campiciano Carlo M	officer	—	—	0	—	—
May 14, 2019	Kenyon Julian Norman	director, officer: Chief Scientific Officer	Stock Options (Right to Buy)	A	9,750,000	$0.01	$82,875.00
May 14, 2019	Kenyon Julian Norman	director, officer: Chief Scientific Officer	Restricted Stock Units	A	9,750,000	—	—
May 14, 2019	Nathanielsz James Andrew	director, officer: CEO, Acting CFO, Chairman	Stock Options (Right to Buy)	A	19,500,000	$0.01	$183,300.00
May 14, 2019	Nathanielsz James Andrew	director, officer: CEO, Acting CFO, Chairman	Restricted Stock Units	A	19,500,000	—	—

Supply Chain of PPCB

RELATIONS

Upstream

European CDMO (Contract Development & Manufacturing Organization)Raw Material Supplier (Bovine Pancreatic Proenzymes)University of Jaén (Spain)University of Granada (Spain)

Downstream

No commercial customers (pre-revenue stage)

Proxies

CytomX Therapeutics, Inc.NASDAQ:CTMX Halozyme Therapeutics, Inc.NASDAQ:HALO Onconova Therapeutics, Inc.NASDAQ:ONTX

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer